English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

The  HLA ‐A11 or ‐A33 allele is found in approximately 18% or 10% of the Asian population, respectively, but each of which is a minor allele worldwide, and therefore no clinical trials were previously conducted. To develop a therapeutic peptide vaccine for each of them, we investigated immunological responses of advanced cancer patients with the  HLA ‐A11 + /A11 +  ( n =  18) or ‐A33 + /A33 +  ( n =  13) allele to personalized peptide vaccine ( PPV ) regimens. The primary sites of  HLA ‐A11+/A11+ or ‐A33+/A33+ patients were the colon ( n =  4 or 2), stomach (2 or 3), breast (3 or 2), lung and pancreas (2 or 2), and so on. For  PPV , a maximum of four peptides were selected from nine different peptides capable of binding to  HLA ‐A11 and ‐A33 molecules based on the pre‐existing peptide‐specific IgG responses. There were no severe adverse events related to  PPV . At the end of the first cycle, peptide‐specific  CTL  responses were augmented in 4/12 or 2/9 of  HLA ‐A11 + /A11 +  or ‐A33 + /A33 +  patients, while peptide‐specific IgG responses were augmented in 6/14 or 4/10 patients, respectively. Clinical responses consisted of four stable diseases and 14 progressive diseases in  HLA ‐A11 + /A11 + patients, versus seven and six in ‐A33 + /A33 + patients, respectively. Further clinical study of  PPV  could be recommended because of the safety and positive immunological responses.

Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11 + or ‐A33 + allele